Aarti Drugs leadership shift: Chairman, MD from Oct 2026

What Aarti Drugs announced

Aarti Drugs Limited has finalised a leadership transition that changes the top executive roles from October 1, 2026. The company said its Chairman, Managing Director and Chief Executive Officer, Prakash M. Patil, will retire at the close of business on September 30, 2026. The board has elevated Rashesh C. Gogri to the position of Chairman while he continues as Managing Director. Alongside this change, Adhish P. Patil has been appointed as Managing Director for a five-year term, effective October 1, 2026.

The set of announcements also included board-level changes involving whole-time director positions and reappointments of senior executives and independent directors for fresh terms. Several of these appointments were stated as subject to shareholder approval at the Annual General Meeting (AGM).

Board meeting that cleared the succession plan

The leadership transition was approved by the Board of Directors at its meeting held on July 31, 2026. At that meeting, the board approved Rashesh C. Gogri’s elevation to Chairman in addition to his existing role as Managing Director. The board also approved the appointment of Adhish P. Patil as Managing Director, effective October 1, 2026.

Aarti Drugs described the change as an orderly succession plan, with Prakash M. Patil choosing early retirement. The company also indicated that after his retirement from executive roles, Prakash M. Patil will remain available for guidance and strategic support during the transition.

Prakash M. Patil to retire on September 30, 2026

Prakash M. Patil is set to retire from his roles as Chairman, Managing Director, and CEO effective September 30, 2026. The company stated that this is ahead of his scheduled term expiry on May 31, 2027. It also noted that he has served as Chairman and Managing Director since 2014, and that he has been associated with the company since inception.

The early retirement was positioned as a measure to facilitate a smooth handover. The board accepted the retirement, citing the need for an orderly succession plan.

Rashesh C. Gogri elevated to Chairman while retaining MD role

From October 1, 2026, Rashesh C. Gogri will assume the position of Chairman of Aarti Drugs. The company also stated that he will retain his existing role as Managing Director. Gogri has been serving as Managing Director since September 2014.

This structure keeps the existing operational hierarchy in place, with the company continuing to run with a promoter-led operating model as described in the disclosed transition notes. The board’s decision effectively adds the chairmanship responsibilities to Gogri’s current executive leadership role.

Adhish P. Patil appointed Managing Director for five years

Adhish P. Patil has been appointed as Managing Director for a five-year term starting October 1, 2026. The company described him as the outgoing Chairman’s son and stated that he is currently the Chief Financial Officer. It also noted that Adhish P. Patil has been CFO since April 2014, and is also referenced as CFO and COO.

The appointment was described as subject to shareholder approval at the ensuing AGM. The company’s framing suggests the move is an internal promotion aligned with the existing hierarchy rather than a structural shift in executive leadership.

Whole-time director change: Uday M. Patil retirement and Nilesh B. Patil appointment

Aarti Drugs also announced that Uday Moreshwar Patil ceased as Whole-time Director, after not seeking reappointment. In his place, Nilesh Bhalchandra Patil was appointed Director and Whole-time Director effective September 26, 2026. The company indicated this whole-time director appointment is for five years, subject to shareholder approval.

These moves reflect a parallel refresh in the board’s executive director positions alongside the CEO-level transition.

Other reappointments approved by the board

In addition to the headline succession changes, the board approved a set of reappointments for senior management and independent directors, each tied to specific effective dates and terms.

Harshit M. Savla was re-appointed as Joint Managing Director for a further five-year period effective June 1, 2027, subject to shareholder approval. Harit P. Shah was also approved for re-appointment as Whole-time Director for a further five-year period effective June 1, 2027, again subject to shareholder approval.

The company also approved the re-appointment of three Independent Directors, Hasmukh B. Dedhia, Ajit E. Venugopalan, and Sandeep M. Joshi, for a second term of five years effective March 29, 2027, subject to shareholder approval.

Shareholder approvals at the 41st AGM on September 26, 2026

Aarti Drugs held its 41st AGM on September 26, 2026. According to the company’s update, shareholders approved the appointment of Nilesh Bhalchandra Patil and Adhish Prakash Patil to key leadership roles.

The AGM approvals connect to the earlier board decisions and help complete the company’s stated process of internal succession and leadership continuity. The company has repeatedly referenced shareholder approval as a condition for certain appointments, reinforcing that the transition is designed to be implemented through formal governance steps.

Key leadership changes and effective dates

Market impact and why the change matters

Aarti Drugs’ disclosures focus on continuity and succession rather than a change in business direction. The company has positioned the retirement of Prakash M. Patil as an early step to ensure a smooth handover. The leadership roles from October 1, 2026 concentrate chairmanship and managing director responsibilities with Rashesh C. Gogri, while also appointing Adhish P. Patil as Managing Director for a defined five-year term.

From a governance standpoint, the company’s repeated references to shareholder approvals at the AGM and to fixed effective dates provide clarity for investors tracking control, accountability, and executive responsibilities. The presence of scheduled reappointments for executive and independent directors, with effective dates in 2027, also indicates that the company is planning board continuity beyond the immediate October 2026 transition.

Conclusion

Aarti Drugs has set a structured leadership transition effective October 1, 2026, anchored by Prakash M. Patil’s retirement on September 30, 2026 and the elevation of Rashesh C. Gogri to Chairman while he continues as Managing Director. Adhish P. Patil’s appointment as Managing Director for five years adds a second MD role within the top leadership group. Over the coming months, investors are likely to track the implementation of the announced effective dates and the company’s AGM-linked approvals and reappointment schedule for 2027.